دورية أكاديمية
أعرض في EDS

Projected Incidence of Hepatobiliary Cancers and Trends Based on Age, Race, and Gender in the United States.

التفاصيل البيبلوغرافية
العنوان: Projected Incidence of Hepatobiliary Cancers and Trends Based on Age, Race, and Gender in the United States.
المؤلفون: Storandt MH; Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA., Tella SH; Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA., Wieczorek MA; Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL 32224, USA., Hodge D; Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL 32224, USA., Elrod JK; Department of Statistics and Data Science, Carnegie Mellon University, Pittsburgh, PA 15213, USA., Rosenberg PS; Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20814, USA., Jin Z; Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA., Mahipal A; Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.; University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA.
المصدر: Cancers [Cancers (Basel)] 2024 Feb 06; Vol. 16 (4). Date of Electronic Publication: 2024 Feb 06.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Background: Identifying the projected incidence of hepatobiliary cancers and recognizing patient cohorts at increased risk can help develop targeted interventions and resource allocation. The expected incidence of subtypes of hepatobiliary cancers in different age groups, races, and genders remains unknown.
Methods: Historical epidemiological data from the Surveillance, Epidemiology, and End Results (SEER) database was used to project future incidence of hepatobiliary malignancies in the United States and identify trends by age, race, and gender. Patients ≥18 years of age diagnosed with a hepatobiliary malignancy between 2001 and 2017 were included. US Census Bureau 2017 National Population projects provided the projected population from 2017 to 2029. Age-Period-Cohort forecasting model was used to estimate future births cohort-specific incidence. All analyses were completed using R Statistical Software.
Results: We included 110381 historical patients diagnosed with a hepatobiliary malignancy between 2001 and 2017 with the following subtypes: hepatocellular cancer (HCC) (68%), intrahepatic cholangiocarcinoma (iCCA) (11.5%), gallbladder cancer (GC) (8%), extrahepatic cholangiocarcinoma (eCCA) (7.6%), and ampullary cancer (AC) (4%). Our models predict the incidence of HCC to double (2001 to 2029) from 4.5 to 9.03 per 100,000, with the most significant increase anticipated in patients 70-79 years of age. In contrast, incidence is expected to continue to decline among the Asian population. Incidence of iCCA is projected to increase, especially in the white population, with rates in 2029 double those in 2001 (2.13 vs. 0.88 per 100,000, respectively; p < 0.001). The incidence of GC among the black population is expected to increase. The incidence of eCCA is expected to significantly increase, especially among the Hispanic population, while that of AC will remain stable.
Discussion: The overall incidence of hepatobiliary malignancies is expected to increase in the coming years, with certain groups at increased risk. These findings may help with resource allocation when considering screening, treatment, and research in the coming years.
References: Clin Gastroenterol Hepatol. 2022 Feb;20(2):283-292.e10. (PMID: 33965578)
Nat Rev Gastroenterol Hepatol. 2021 Apr;18(4):223-238. (PMID: 33349658)
Clin Epidemiol. 2014 Mar 07;6:99-109. (PMID: 24634588)
N Engl J Med. 2022 Jul 21;387(3):205-216. (PMID: 35658024)
CA Cancer J Clin. 2021 Jan;71(1):7-33. (PMID: 33433946)
N Engl J Med. 2021 Mar 25;384(12):1113-1124. (PMID: 33185364)
Hepat Med. 2019 Nov 15;11:159-178. (PMID: 31814783)
J Registry Manag. 2011 Winter;38(4):201-5. (PMID: 23270094)
Am Soc Clin Oncol Educ Book. 2014;:112-5. (PMID: 24857067)
Int J Mol Sci. 2023 Jan 15;24(2):. (PMID: 36675217)
J Natl Compr Canc Netw. 2018 Apr;16(4):370-376. (PMID: 29632056)
Clin Gastroenterol Hepatol. 2022 Aug;20(8):1687-1700.e4. (PMID: 34474162)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
CA Cancer J Clin. 2020 Jan;70(1):7-30. (PMID: 31912902)
Expert Rev Gastroenterol Hepatol. 2011 Jun;5(3):365-70. (PMID: 21651354)
J Natl Cancer Inst. 2021 Nov 29;113(12):1670-1682. (PMID: 34698839)
Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2296-302. (PMID: 25146089)
Clin Mol Hepatol. 2023 Jan;29(1):120-134. (PMID: 35957547)
CA Cancer J Clin. 2018 Jan;68(1):31-54. (PMID: 29160902)
JAMA. 2020 Mar 10;323(10):970-975. (PMID: 32119076)
Nat Rev Dis Primers. 2022 Oct 27;8(1):69. (PMID: 36302789)
Gastroenterology. 2018 May;154(6):1719-1728.e5. (PMID: 29549041)
Gastroenterology. 2013 Dec;145(6):1215-29. (PMID: 24140396)
J Clin Oncol. 2016 May 20;34(15):1787-94. (PMID: 27044939)
Clin Res Hepatol Gastroenterol. 2020 Nov;44(6):885-893. (PMID: 32359831)
CA Cancer J Clin. 2023 Jan;73(1):17-48. (PMID: 36633525)
MMWR Recomm Rep. 2023 Mar 10;72(1):1-25. (PMID: 36893044)
N Engl J Med. 2021 Mar 18;384(11):989-1002. (PMID: 33567185)
World J Gastroenterol. 2021 Sep 21;27(35):5803-5821. (PMID: 34629804)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
J Hepatol. 2019 Jul;71(1):104-114. (PMID: 30910538)
Aliment Pharmacol Ther. 2021 May;53(9):977-984. (PMID: 33721336)
فهرسة مساهمة: Keywords: cholangiocarcinoma; gallbladder cancer; hepatocellular cancer; incidence
تواريخ الأحداث: Date Created: 20240224 Latest Revision: 20240227
رمز التحديث: 20240227
مُعرف محوري في PubMed: PMC10886529
DOI: 10.3390/cancers16040684
PMID: 38398075
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers16040684